The urgent need for an early-warning system to monitor tissue pCO2 and alert medical caregivers to tissue hypoperfusion is clear and immediate, with the potential to save countless lives. ExoStat Medical has developed a novel, proprietary technology to meet this crucially important—and rapidly growing—need.
A noninvasive monitoring device, the MicroTrend™ System features a micro sensor embedded in a hands-free mouth clip located in the buccal mucosa tissue of the mouth. The sensor retrieves a continuous stream of data to measure partial pressure carbon dioxide (pCO2), an early indicator of tissue hypoperfusion. Patient populations include those in ERs, ICUs, perioperative units, dialysis centers, burn centers, nursing homes, recovery rooms, ventilation weaning units and environments where the critically ill and injured are located.
Sepsis-related illnesses such as hypoxia and hypercapnia represent a significant medical challenge and a potentially major market opportunity in addressing this pervasive, life threatening condition. According to the US Sepsis Alliance1:
In 2016, ExoStat Medical engaged Deloitte Consulting to provide ExoStat Medical with a three-phased market analysis that quantified the addressable markets in three subsets:
The report delivered by Deloitte included potential units sold, competition, pricing considerations, and other pertinent information. In summary, the revenue potential for the addressable market is substantial and there is currently no competitor for a real time, point of care, non-invasive, 8-hour monitoring sensor for tissue hypoperfusion.
The market potential for the MicroTrend System can only be estimated at this time as no direct competition (or comparable device) currently exists. All novel and disruptive products require time to educate users and time for supply to match demand. ExoStat has allocated valuable time and resources to the understanding of, and preparation for, these challenges.
1 Global Sepsis Alliance
2 National Inpatient Hospital Costs. Agency for Healthcare and CDC. gov.
3 In early 2016, ExoStat engaged Deloitte Consulting to provide an assessment of the domestic and international markets for the MicroTrend™ System, basing revenue projections on preliminary pricing assumptions and a reasonable and timely product rollout.
*In 2019, Medscape reported the costs as more than $62 billion
Tissue Hypoperfusion is a medical emergency. There is a large, unmet market for a technology solution that addresses this need. The MicroTrend System is the solution. Below are the market advantages of this device:
ExoStat Medical has established relationships with medical institutions and healthcare professionals, including physicians and clinical research experts who are expected to become early adopters of the MicroTrend System. Our highly skilled R&D team has more than 50 years of combined product design experience, and our company is guided by a highly experienced management team and Board of Directors. ExoStat Medical is fully funded and has no debt.